EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin



Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin



Journal of Antimicrobial ChemoTherapy 52(4): 656-662



Objectives: AmBisome and micafungin were used alone and in combination in a series of studies designed to identify any additive or antagonistic effects of combination antifungal therapy. Methods: Immune-suppressed mice were infected either intravenously or intranasally with Aspergillus fumigatus. Micafungin, liposomal amphotericin B or both drugs together were administered for 7 days. Parameters of efficacy included survival and tissue burden of A. fumigatus. Results: Whilst each drug was effective in murine aspergillosis, additive effects were observed only in reduction of tissue burden in limited experimental conditions. No antagonism was seen. Conclusions: The present studies neither encourage nor discourage clinical use of combination therapy. Clinical trials are suggested before combined therapy is routinely adopted.

(PDF emailed within 0-6 h: $19.90)

Accession: 011874203

Download citation: RISBibTeXText

PMID: 12972452

DOI: 10.1093/jac/dkg425



Related references

Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 53(8): 3508-3510, 2009

Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 52(5): 1868-1870, 2008

Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrobial Agents and ChemoTherapy 49(12): 4867-4875, 2005

Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis. Antimicrobial Agents and ChemoTherapy 50(4): 1567-1569, 2006

Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 52(11): 4178-4180, 2008

Successful treatment of rhino-orbital mucormycosis by a new combination therapy with liposomal amphotericin B and micafungin. Auris, Nasus, Larynx 39(2): 224-228, 2012

Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model. Journal of Antimicrobial ChemoTherapy 64(2): 379-382, 2009

Successful treatment of azole-refractory Candida guilliermondii fungemia with a combination therapy of micafungin and liposomal amphotericin B. Japanese Journal of Clinical Hematology 49(2): 94-98, 2008

Combination therapy with caspofungin and liposomal amphotericin B for invasive aspergillosis. Pediatric Infectious Disease Journal 22(7): 653-656, 2003

Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatric Infectious Disease Journal 26(4): 364-366, 2007

Prophylactic efficacy of aerosolized liposomal and non-liposomal amphotericin B in murine pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy 34(6): 1001-1013, 1994

Sino-orbital aspergillosis treated with combination antifungal therapy. Successful therapy after failure with amphotericin B and surgery. JAMA 244(8): 814-815, 1980

Combination antifungal therapy with FK463 plus amphotericin B in treatment of experimental pulmonary aspergillosis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 581, 1999

Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. Journal of Antimicrobial ChemoTherapy 34(6): 1001-1013, 1994

Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery. Journal of Medical Microbiology 51(1): 70-75, 2002